BR0315134A - Uses of il-21 and an il-21 Polypeptide - Google Patents

Uses of il-21 and an il-21 Polypeptide

Info

Publication number
BR0315134A
BR0315134A BR0315134-4A BR0315134A BR0315134A BR 0315134 A BR0315134 A BR 0315134A BR 0315134 A BR0315134 A BR 0315134A BR 0315134 A BR0315134 A BR 0315134A
Authority
BR
Brazil
Prior art keywords
diseases
polypeptide
allergic
conditions
eosinophils
Prior art date
Application number
BR0315134-4A
Other languages
Portuguese (pt)
Inventor
John Romer
Niels Peter Hundahl Moller
Kresten Skak
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0315134A publication Critical patent/BR0315134A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"USOS DE IL-21 E DE UM POLIPEPTìDEO DE IL-21". A invenção refere-se à administração de IL-21 para gerenciamento, tratamento e prevenção de doenças ou condições onde eosinófilos estão envolvidos em uma resposta protetora, por exemplo reações alérgicas, doenças alérgicas, condições alérgicas, e doenças parasíticas."USES OF IL-21 AND AN IL-21 POLYPEPTIDE". The invention relates to the administration of IL-21 for management, treatment and prevention of diseases or conditions where eosinophils are involved in a protective response, for example allergic reactions, allergic diseases, allergic conditions, and parasitic diseases.

BR0315134-4A 2002-10-11 2003-10-13 Uses of il-21 and an il-21 Polypeptide BR0315134A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200201546 2002-10-11
DKPA200201587 2002-10-16
US41922502P 2002-10-17 2002-10-17
PCT/DK2003/000691 WO2004032953A1 (en) 2002-10-11 2003-10-13 Treatment of allergic conditions by use of il 21

Publications (1)

Publication Number Publication Date
BR0315134A true BR0315134A (en) 2005-08-16

Family

ID=32096538

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315134-4A BR0315134A (en) 2002-10-11 2003-10-13 Uses of il-21 and an il-21 Polypeptide

Country Status (8)

Country Link
EP (1) EP1553970A1 (en)
JP (1) JP2006525223A (en)
AU (1) AU2003273758A1 (en)
BR (1) BR0315134A (en)
CA (1) CA2501807A1 (en)
MX (1) MXPA05003729A (en)
PL (1) PL376118A1 (en)
WO (1) WO2004032953A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4664684B2 (en) 2002-12-13 2011-04-06 ザイモジェネティクス， インコーポレイテッド Production of IL-21 in prokaryotic hosts
AU2005244942A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
ES2360728T3 (en) * 2005-09-22 2011-06-08 Inserm (Institut National De La Santé Et De La Recherche Medicale) METHODS OF USE OF IL-21.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082433A4 (en) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins-21 and 22
CN1927883B (en) * 1999-03-09 2011-09-21 津莫吉尼蒂克斯公司 Novel cytokine zalpha11 ligand
EP1806404B1 (en) * 2000-07-27 2010-08-18 Wyeth LLC Use of IL-10 receptor beta antagonistic antibodies for inhibiting IL-TIF/IL-21 induction of acute phase proteins
DK1432431T3 (en) * 2001-10-04 2017-07-10 Genetics Inst Llc Methods and compositions for modulating interleukin-21 activity
AU2003230834A1 (en) * 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses

Also Published As

Publication number Publication date
AU2003273758A1 (en) 2004-05-04
JP2006525223A (en) 2006-11-09
WO2004032953A1 (en) 2004-04-22
CA2501807A1 (en) 2004-04-22
PL376118A1 (en) 2005-12-12
MXPA05003729A (en) 2005-06-17
EP1553970A1 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
BR0312421A (en) Use of cept inhibitors and optionally hmg coa reductase inhibitors and / or antihypertensive agents
ATE362766T1 (en) APOLIPOPROTEIN A-I AGONISTS AND THEIR USE IN THE TREATMENT OF DISLIPIDEMIC DISEASES
BR0313041A (en) Compounds; pharmaceutical compositions; method for the treatment and / or prophylaxis of diseases that are associated with cb1 receptor modulation; and use of compounds
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2003030934A3 (en) Cpg formulations and related methods
NO20050807L (en) Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders
ATE508114T1 (en) ISOINDOLYL COMPOUNDS SUBSTITUTED WITH N-ALKYLHYDROXAMIC ACIDS AND THEIR PHARMACEUTICAL USE
BRPI0517015A (en) compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BR0208636A (en) Therapeutic agent for chronic arthritic diseases of childhood-related diseases
BRPI0517481A (en) method for treating, controlling or preventing a protozoan parasitic disease or disorder, and, pharmaceutical composition
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
DOP2002000429A (en) IMIDAZOTRIAZINAS
NO20034056D0 (en) Proliferative diseases
BR0213540A (en) Compounds, method for treating a patient's illness or disorder and a pharmaceutical composition comprising them
BRPI0407662B8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CY1113894T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING Roflumilast and Levocetirizine
BRPI0411176A (en) pharmaceutical combination consisting of modafinil and another drug
MXPA06002722A (en) A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug.
BR0313413A (en) Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease
BR9916190A (en) Use of kqt1 channel inhibitors for the preparation of a medicine for the treatment of diseases, which are caused by helminths and ectoparasites
BRPI0408889A (en) Clusterin use for treatment and / or prevention of peripheral neurological diseases
HRP20031057B1 (en) Tablet comprising cetirizine and pseudoephedrine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]